You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Safety and tolerability of once-daily umeclidinium/vilanterol 125/25 mcg and umeclidinium 125 mcg in patients with chronic obstructive pulmonary disease: results from a 52-week, randomized, double-blind, placebo-controlled study
|
|---|---|
| Published in |
Respiratory Research, July 2014
|
| DOI | 10.1186/1465-9921-15-78 |
| Pubmed ID | |
| Authors |
James F Donohue, Dennis Niewoehner, Jean Brooks, Dianne O’Dell, Alison Church |
| Abstract |
The long-acting muscarinic antagonist (LAMA) umeclidinium (UMEC) and the combination of UMEC with the long-acting β2-agonist (LABA) vilanterol (UMEC/VI) are approved maintenance treatments for chronic obstructive pulmonary disease (COPD) in the US and EU. They are not indicated for the treatment of asthma. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 108 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 2 | 2% |
| Spain | 2 | 2% |
| Australia | 1 | <1% |
| Unknown | 103 | 95% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 17 | 16% |
| Other | 16 | 15% |
| Researcher | 12 | 11% |
| Student > Ph. D. Student | 11 | 10% |
| Student > Bachelor | 10 | 9% |
| Other | 26 | 24% |
| Unknown | 16 | 15% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 49 | 45% |
| Pharmacology, Toxicology and Pharmaceutical Science | 10 | 9% |
| Agricultural and Biological Sciences | 7 | 6% |
| Nursing and Health Professions | 6 | 6% |
| Economics, Econometrics and Finance | 3 | 3% |
| Other | 10 | 9% |
| Unknown | 23 | 21% |
Attention Score in Context
This research output has an Altmetric Attention Score of 8. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 16 December 2020.
All research outputs
#4,660,989
of 25,382,440 outputs
Outputs from Respiratory Research
#582
of 3,062 outputs
Outputs of similar age
#42,855
of 241,397 outputs
Outputs of similar age from Respiratory Research
#3
of 35 outputs
Altmetric has tracked 25,382,440 research outputs across all sources so far. Compared to these this one has done well and is in the 81st percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,062 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 7.9. This one has done well, scoring higher than 80% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 241,397 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 82% of its contemporaries.
We're also able to compare this research output to 35 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 88% of its contemporaries.